BPC-157 human trials: what has actually been studied
The animal literature is decades deep. The human trial base is much smaller. Here is the honest map.
TL;DR
- Most BPC-157 research is in animals — rats, mice, and rabbits — across gastric protection, tendon healing, and tissue repair.
- Published human trials are limited and small; most use the molecule for orthopedic or gastrointestinal indications.
- As of September 2026, FDA's advisory committee has voted to recommend BPC-157 for the Section 503A bulk drug substances list. FDA has not yet made a final decision.
What it is
BPC-157 stands for "body protection compound 157." It is a synthetic peptide derived from a protein found in human gastric juice — the acidic fluid your stomach produces. Picture it as a fragment that the body uses for self-repair in the digestive tract. Researchers have studied it for the broader question: can a peptide that protects the gut also help repair tissue elsewhere? The animal evidence on that question is large; the human evidence is small.
How it works
The proposed mechanism centers on angiogenesis (in plain English: the formation of new small blood vessels) and fibroblast (in plain English: skin and connective-tissue repair) signaling. In animal studies, BPC-157 appears to support the early phases of healing in tendon, ligament, gut, and brain tissue — the parts of the repair process that depend on new blood supply and on cells that lay down collagen. The mechanism story is consistent across study types. Translating that story into a specific dose for a specific human indication is the harder problem.
Who asks about it
People come to BPC-157 after reading about its tendon, ligament, or gut healing potential. The next question — "is there human evidence?" — is the right one. The honest answer requires distinguishing the rich animal literature from the much sparser human trial base.
What the research says
A 2022 review summarizing 30 years of BPC-157 research found dozens of animal studies covering tendon, ligament, gut, and central nervous system models, with a much smaller subset of published human reports (Sikiric et al., Curr Pharm Des, 2022). A few human trials are registered on ClinicalTrials.gov, including investigations of orthopedic and gastrointestinal indications (NCT04318834, ClinicalTrials.gov). Long-term safety data in humans are limited.
What to know before considering it
BPC-157 was placed in FDA Category 2 in 2023. FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, BPC-157 is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Anyone considering it should discuss the current regulatory status and the limited human evidence base with a physician.
The Halftime POV
BPC-157 is the molecule where the gap between online enthusiasm and clinical evidence is largest. The mechanism work is real, the animal results are interesting, and the human trial pipeline is small. We cover it because patients ask about it — and because the honest version of the answer is more useful than the hype version. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Related reading:
- BPC-157: what this body protection compound is
- BPC-157 and the Category 2 question
- Category 1 vs Category 2 peptides: the access framework
FAQ
Q: Are there human trials for BPC-157? A: A small number — most published BPC-157 evidence is from animal studies. A handful of registered human trials exist, but the human data are limited compared to the animal literature, which spans decades.
Q: Is BPC-157 FDA-approved? A: No. BPC-157 is not FDA-approved. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Q: Why is most BPC-157 research in animals? A: BPC-157 was first studied in the gastric protection literature in animals starting in the 1990s. Translating animal regenerative findings into human trials requires significant funding and a clear regulatory pathway — both of which have been limited for this molecule.
Q: Will the regulatory status change? A: FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, BPC-157 is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Disclaimer
As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Stable gastric pentadecapeptide BPC 157: 30-year-overview — Sikiric et al., Curr Pharm Des, 2022
- Pentadecapeptide BPC 157 Treatment of Patients with Inflammatory Bowel Disease — ClinicalTrials.gov NCT04318834
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Are there human trials for BPC-157?
A small number — most published BPC-157 evidence is from animal studies. A handful of registered human trials exist, but the human data are limited compared to the animal literature, which spans decades.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Why is most BPC-157 research in animals?
BPC-157 was first studied in the gastric protection literature in animals starting in the 1990s. Translating animal regenerative findings into human trials requires significant funding and a clear regulatory pathway — both of which have been limited for this molecule.
Keep reading
For living longer, and still feeling like yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.